Tumour hypoxia determines the potential of combining mTOR and autophagy inhibitors to treat mammary tumours

British Journal of Cancer

Volumn 109, Issue 10, 2013, Pages 2597-2606

  Seront, E ^a,b   Boidot, R ^a   Bouzin, C ^a   Karroum, O ^a   Jordan, B F ^a   Gallez, B ^a   MacHiels, J P ^a,b   Feron, O ^a  

^a UNIVERSITÉ CATHOLIQUE DE LOUVAIN   (Belgium)

^b CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

CHLOROQUINE; MAMMALIAN TARGET OF RAPAMYCIN; RAPAMYCIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; ARTICLE; AUTOPHAGY; BREAST CANCER; CANCER CELL; CANCER INHIBITION; CELL STRAIN MCF 7; CONTROLLED STUDY; DRUG EFFECT; DRUG POTENCY; DRUG POTENTIATION; DRUG SENSITIZATION; FEMALE; HUMAN; HUMAN CELL; HYPOXEMIA; IN VITRO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; REOXYGENATION; TUMOR HYPOXIA; TUMOR VASCULARIZATION; TUMOR VOLUME; TUMOR XENOGRAFT;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; AUTOPHAGY; BREAST NEOPLASMS; CELL HYPOXIA; CHLOROQUINE; FEMALE; HUMANS; MAMMARY NEOPLASMS, EXPERIMENTAL; MICE, NUDE; SIROLIMUS; TOR SERINE-THREONINE KINASES; TUMOR CELLS, CULTURED; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84887836133     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2013.644     Document Type: Article

References (42)

1. Amaravadi RK, Lippincott-Schwartz J, Yin XM, Weiss WA, Takebe N, Timmer W, DiPaola RS, Lotze MT, White E (2011) Principles and current strategies for targeting autophagy for cancer treatment. Clin Cancer Res 17(4): 654-666.
2. Amaravadi RK, Yu D, Lum JJ, Bui T, Christophorou MA, Evan GI, Thomas-Tikhonenko A, Thompson CB (2007) Autophagy inhibition enhances therapy-induced apoptosis in a Myc-induced model of lymphoma. J Clin Invest 117(2): 326-336.
3. Andre F, Campone M, O'Regan R, Manlius C, Massacesi C, Sahmoud T, Mukhopadhyay P, Soria JC, Naughton M, Hurvitz SA (2010) Phase I study of everolimus plus weekly paclitaxel and trastuzumab in patients with metastatic breast cancer pretreated with trastuzumab. J Clin Oncol 28(34): 5110-5115.
4. Baselga J, Semiglazov V, van DP, Manikhas A, Bellet M, Mayordomo J, Campone M, Kubista E, Greil R, Bianchi G, Steinseifer J, Molloy B, Tokaji E, Gardner H, Phillips P, Stumm M, Lane HA, Dixon JM, Jonat W, Rugo HS (2009) Phase II randomized study of neoadjuvant everolimus plus letrozole compared with placebo plus letrozole in patients with estrogen receptor-positive breast cancer. J Clin Oncol 27(16): 2630-2637.
5. Bellot G, Garcia-Medina R, Gounon P, Chiche J, Roux D, Pouyssegur J, Mazure NM (2009) Hypoxia-induced autophagy is mediated through hypoxia-inducible factor induction of BNIP3 and BNIP3L via their BH3 domains. Mol Cell Biol 29(10): 2570-2581.
6. 2 availability on human cancer. Nat Rev Cancer 8(12): 967-975.
7. Boidot R, Vegran F, Meulle A, Le BA, Dessy C, Sonveaux P, Lizard-Nacol S, Feron O (2012) Regulation of monocarboxylate transporter MCT1 expression by p53 mediates inward and outward lactate fluxes in tumors. Cancer Res 72(4): 939-948.
8. Bouzin C, Feron O (2007) Targeting tumor stroma and exploiting mature tumor vasculature to improve anti-cancer drug delivery. Drug Resist Updat 10(3): 109-120.
9. Bristow RG, Hill RP (2008) Hypoxia and metabolism. Hypoxia, DNA repair and genetic instability. Nat Rev Cancer 8(3): 180-192.
10. Chan S, Scheulen ME, Johnston S, Mross K, Cardoso F, Dittrich C, Eiermann W, Hess D, Morant R, Semiglazov V, Borner M, Salzberg M, Ostapenko V, Illiger HJ, Behringer D, Bardy-Bouxin N, Boni J, Kong S, Cincotta M, Moore L (2005) Phase II study of temsirolimus (CCI-779), a novel inhibitor of mTOR, in heavily pretreated patients with locally advanced or metastatic breast cancer. J Clin Oncol 23(23): 5314-5322.
11. Crokart N, Radermacher K, Jordan BF, Baudelet C, Cron GO, Gregoire V, Beghein N, Bouzin C, Feron O, Gallez B (2005) Tumor radiosensitization by antiinflammatory drugs: evidence for a new mechanism involving the oxygen effect. Cancer Res 65(17): 7911-7916.
12. Dalby KN, Tekedereli I, Lopez-Berestein G, Ozpolat B (2010) Targeting the prodeath and prosurvival functions of autophagy as novel therapeutic strategies in cancer. Autophagy 6(3): 322-329.
13. Dancey J (2010) mTOR signaling and drug development in cancer. Nat Rev Clin Oncol 7(4): 209-219.
14. Easton JB, Houghton PJ (2006) mTOR and cancer therapy. Oncogene 25(48): 6436-6446.
15. Eng CH, Abraham RT (2011) The autophagy conundrum in cancer: influence of tumorigenic metabolic reprogramming. Oncogene 30(47): 4687-4696.
16. Eskelinen EL (2011) The dual role of autophagy in cancer. Curr Opin Pharmacol 11(4): 294-300.
17. Feron O (2004) Targeting the tumor vascular compartment to improve conventional cancer therapy. Trends Pharmacol Sci 25(10): 536-542.
18. Fleming GF, Ma CX, Huo D, Sattar H, Tretiakova M, Lin L, Hahn OM, Olopade FO, Nanda R, Hoffman PC, Naughton MJ, Pluard T, Conzen SD, Ellis MJ (2012) Phase II trial of temsirolimus in patients with metastatic breast cancer. Breast Cancer Res Treat 136(2): 355-363.
19. Fokas E, Im JH, Hill S, Yameen S, Stratford M, Beech J, Hackl W, Maira SM, Bernhard EJ, McKenna WG, Muschel RJ (2012) Dual inhibition of the PI3K/mTOR pathway increases tumor radiosensitivity by normalizing tumor vasculature. Cancer Res 72(1): 239-248.
20. Harris AL (2002) Hypoxia-a key regulatory factor in tumour growth. Nat Rev Cancer 2(1): 38-47.
21. Hu YL, Delay M, Jahangiri A, Molinaro AM, Rose SD, Carbonell WS, Aghi MK (2012) Hypoxia-induced autophagy promotes tumor cell survival and adaptation to antiangiogenic treatment in glioblastoma. Cancer Res 72(7): 1773-1783.
22. Janku F, McConkey DJ, Hong DS, Kurzrock R (2011) Autophagy as a target for anticancer therapy. Nat Rev Clin Oncol 8(9): 528-539.
23. Mazure NM, Pouyssegur J (2010) Hypoxia-induced autophagy: cell death or cell survival? Curr Opin Cell Biol 22(2): 177-180.
24. Mehrpour M, Esclatine A, Beau I, Codogno P (2010) Overview of macroautophagy regulation in mammalian cells. Cell Res 20(7): 748-762.
25. Milani M, Harris AL (2008) Targeting tumour hypoxia in breast cancer. Eur J Cancer 44(18): 2766-2773.
26. O'Regan R, Hawk NN (2011) mTOR inhibition in breast cancer: unraveling the complex mechanisms of mTOR signal transduction and its clinical implications in therapy. Expert Opin Ther Targets 15(7): 859-872.
27. Pries AR, Hopfner M, le NF, Dewhirst MW, Secomb TW (2010) The shunt problem: control of functional shunting in normal and tumour vasculature. Nat Rev Cancer 10(8): 587-593.
28. Rouschop KM, Ramaekers CH, Schaaf MB, Keulers TG, Savelkouls KG, Lambin P, Koritzinsky M, Wouters BG (2009) Autophagy is required during cycling hypoxia to lower production of reactive oxygen species. Radiother Oncol 92(3): 411-416.
29. Rouschop KM, van den Beucken T, Dubois L, Niessen H, Bussink J, Savelkouls K, Keulers T, Mujcic H, Landuyt W, Voncken JW, Lambin P, van der Kogel AJ, Koritzinsky M, Wouters BG (2010) The unfolded protein response protects human tumor cells during hypoxia through regulation of the autophagy genes MAP1LC3B and ATG5. J Clin Invest 120(1): 127-141.
30. Semenza GL (2012) Hypoxia-inducible factors: mediators of cancer progression and targets for cancer therapy. Trends Pharmacol Sci 33(4): 207-214.
31. Seront E, Pinto A, Bouzin C, Bertrand L, Machiels JP, Feron O (2013) PTEN deficiency is associated with reduced sensitivity to mTOR inhibitor in human bladder cancer through the unhampered feedback loop driving PI3K/Akt activation. Br J Cancer 109(6): 1586-1592.
32. Sonveaux P, Dessy C, Martinive P, Havaux X, Jordan BF, Gallez B, Gregoire V, Balligand JL, Feron O (2004) Endothelin-1 is a critical mediator of myogenic tone in tumor arterioles: implications for cancer treatment. Cancer Res 64(9): 3209-3214.
33. Tabernero J, Rojo F, Calvo E, Burris H, Judson I, Hazell K, Martinelli E, Cajal S, Jones S, Vidal L, Shand N, Macarulla T, Ramos FJ, Dimitrijevic S, Zoellner U, Tang P, Stumm M, Lane HA, Lebwohl D, Baselga J (2008) Dose-and schedule-dependent inhibition of the mammalian target of rapamycin pathway with everolimus: a phase I tumor pharmacodynamic study in patients with advanced solid tumors. J Clin Oncol 26(10): 1603-1610.
34. Thomson AW, Turnquist HR, Raimondi G (2009) Immunoregulatory functions of mTOR inhibition. Nat Rev Immunol 9(5): 324-337.
35. Vaupel P (2008) Hypoxia and aggressive tumor phenotype: implications for therapy and prognosis. Oncologist 13(Suppl 3): 21-26.
36. Vaupel P, Mayer A, Briest S, Hockel M (2005) Hypoxia in breast cancer: role of blood flow, oxygen diffusion distances, and anemia in the development of oxygen depletion. Adv Exp Med Biol 566: 333-342.
37. Vegran F, Boidot R, Michiels C, Sonveaux P, Feron O (2011) Lactate influx through the endothelial cell monocarboxylate transporter MCT1 supports an NF-kappaB/IL-8 pathway that drives tumor angiogenesis. Cancer Res 71(7): 2550-2560.
38. Workman P, Aboagye EO, Balkwill F, Balmain A, Bruder G, Chaplin DJ, Double JA, Everitt J, Farningham DA, Glennie MJ, Kelland LR, Robinson V, Stratford IJ, Tozer GM, Watson S, Wedge SR, Eccles SA (2010) Guidelines for the welfare and use of animals in cancer research. Br J Cancer 102(11): 1555-1577.
39. Wouters BG, Koritzinsky M (2008) Hypoxia signalling through mTOR and the unfolded protein response in cancer. Nat Rev Cancer 8(11): 851-864.
40. Xue Q, Hopkins B, Perruzzi C, Udayakumar D, Sherris D, Benjamin LE (2008) Palomid 529, a novel small-molecule drug, is a TORC1/TORC2 inhibitor that reduces tumor growth, tumor angiogenesis, and vascular permeability. Cancer Res 68(22): 9551-9557.
41. Yi H, Liang B, Jia J, Liang N, Xu H, Ju G, Ma S, Liu X (2013) Differential roles of miR-199a-5p in radiation-induced autophagy in breast cancer cells. FEBS Lett 587(5): 436-443.
42. Zhang Q, Bindokas V, Shen J, Fan H, Hoffman RM, Xing HR (2011) Time-course imaging of therapeutic functional tumor vascular normalization by antiangiogenic agents. Mol Cancer Ther 10(7): 1173-1184.